The Supreme Court limited cancer lawsuits against Bayer's Monsanto over Roundup weedkiller. Glyphosate is the most commonly used herbicide in agriculture. People claim it gave them cancer. Bayer claims it didn't. The justices picked a side on who gets to sue.
Bayer bought Monsanto in 2018 for $63 billion. They inherited tens of thousands of lawsuits claiming Roundup caused non-Hodgkin lymphoma. The company has already paid out billions in settlements. They kept insisting the science was on their side while cutting checks to people who said the product destroyed their lives. Bold strategy.
The Supreme Court ruling shields Bayer from certain state-law claims because the EPA approved glyphosate. Federal regulators said it was safe, so now some plaintiffs can't argue otherwise in state court. This is called preemption. It means the government's stamp of approval functions as a legal forcefield even when people are dying.
Retail traders saw this news and immediately started googling whether to buy Bayer stock. They will spend forty-five minutes reading conflicting articles about herbicide litigation risk. They will check three different financial subreddits. Then they will buy two shares at market open and watch it drop 3% by lunch.
The EPA has maintained that glyphosate does not cause cancer when used as directed. The International Agency for Research on Cancer classified it as probably carcinogenic to humans in 2015. Two different organizations looked at the same chemical and reached opposite conclusions. One of them is wrong or lying or both.
Bayer stock will move based on earnings, European energy prices, and currency fluctuations. It will not move based on this ruling. But some guy in Michigan will buy puts anyway because he read a headline about lawsuits and thinks he cracked the code.
Photo by on Unsplash
Leave a Comment